A novel form of anti-angiogenic molecular antibody drug induces apoptosis in Myeloma cells after cultivation upon endothelial feeder cells

2021 ◽  
pp. 106617
Author(s):  
Yavar Yousefi ◽  
Zohreh Mortezania ◽  
Mojdeh Abolmolouki ◽  
Amin Daemi
Keyword(s):  
Feeder Cells ◽  
Myeloma Cells ◽  
Antibody Drug

HDP-101, anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells

2020 ◽  
pp. molcanther.0287.2020
Author(s):  
Vianihuini Figueroa-Vazquez ◽  
Jonathan Ko ◽  
Christian Breunig ◽  
Anja Baumann ◽  
Nicola Giesen ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Cell Death ◽  
Antibody Drug Conjugate ◽  
Myeloma Cells ◽  
Induce Cell Death ◽  
Drug Conjugate ◽  
Antibody Drug

scholarly journals Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells

2016 ◽  
Vol 126 (12) ◽  
pp. 4640-4653 ◽  
Author(s):  
Daniel W. Sherbenou ◽  
Blake T. Aftab ◽  
Yang Su ◽  
Christopher R. Behrens ◽  
Arun Wiita ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Antibody Drug Conjugate ◽  
Myeloma Cells ◽  
Drug Conjugate ◽  
Antibody Drug

Involvement of GER in Friend leukemia virus assembly in high-pressure frozen cells

1990 ◽  
Vol 48 (3) ◽  
pp. 590-591
Author(s):  
W. Djaczenko ◽  
M. Müller ◽  
A. Benedetto ◽  
G. Carbone
Keyword(s):  
High Pressure ◽  
Virus Assembly ◽  
Leukemia Virus ◽  
Leukemia Cells ◽  
Serial Sections ◽  
Myeloma Cells ◽  
Virus Particles ◽  
Friend Leukemia ◽  
Carbon Coated ◽  
Friend Leukemia Virus

A thickening of ER membranes in murine myeloma cells was attributed by de Harven to the assembly of intracisternal virus particles. We observed similar thickening of GER membranes in Friend leukemia cells (FLC) apparently associated with Friend leukemia virus (FLV) assembly. We reinvestigated the problem of GER involvement in FLV assembly using high pressure cryofixed FLC.FLC (745A clone growing in suspension and FF clone growing in monolayer) were immersed in Hexadecene (Fluka, Switzerland) and rapidly frozen in Balzers HPM 010 freezing machine working at 2200 bar. All cells were freeze substituted at -90°C in 2% OsO4 in absolute acetone. Serial sections cut to avoid misinterpretations due to the geometry of sections, were collected on carbon coated 100 mesh grids.

ASCO-GU 2019: Metastasierte Urothelkarzinome

2019 ◽  
Vol 10 (03) ◽  
pp. 140-141
Author(s):  
Alexander Kretzschmar
Keyword(s):  
San Francisco ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Chapel Hill ◽  
Antibody Drug

Die Therapielandschaft des metastasierten Urothelkarzinoms hat sich seit der Zulassung der ersten Immun-Checkpoint-Inhibitoren verändert. Die neuen Therapien sind deutlich effektiver, allerdings erreichen die Responseraten der neuen Therapien nur bis zu etwa 30 %, beklagte Prof. Matthew Milowsky, Chapel Hill/USA, auf einer Oral Abstract Session auf dem ASCO-GU. In San Francisco gaben erste Vorträge und Poster bereits einen Einblick, wovon diejenigen Patienten profitieren könnten, die auf die etablierten Chemotherapien und die neuen Immuntherapien nicht ansprechen. Manche Onkologen sprechen bereits von der „Post-Checkpoint-Ära”. Als Kandidaten werden vor allem Antikörper-Wirkstoff-Konjugate (antibody-drug conjugates; ADC) gehandelt – und zwar nicht nur zur Therapie des metastasierten Blasenkarzinoms.

Design, 22-step synthesis, and evaluation of highly potent D-ring modified and linker-equipped analogs of spongistatin 1

2018 ◽  
Author(s):  
James Leighton ◽  
Linda M. Suen ◽  
Makeda A. Tekle-Smith ◽  
Kevin S. Williamson ◽  
Joshua R. Infantine ◽  
...  
Keyword(s):  
Targeted Delivery ◽  
Functional Group ◽  
Human Cancer ◽  
Natural Sources ◽  
Spongistatin 1 ◽  
Human Cancer Cell Lines ◽  
Drug Conjugates ◽  
Attractive Candidate ◽  
Complex Fragment ◽  
Antibody Drug

With an average GI50 value against the NCI panel of 60 human cancer cell lines of 0.12 nM, spongistatin 1 is among the most potent anti-proliferative agents ever discovered rendering it an attractive candidate for development as a payload for antibody-drug conjugates and other targeted delivery approaches. It is unavailable from natural sources and its size and complex stereostructure render chemical synthesis highly time- and resource-intensive, however, and its development requires more efficient and step-economical synthetic access. Using novel and uniquely enabling direct complex fragment coupling alkallyl- and crotylsilylation reactions, we have developed a 22-step synthesis of a rationally designed D-ring modified analog of spongistatin 1 that is equipotent with the natural product, and have used that synthesis to establish that the C(15) acetate may be replaced with a linker functional group-bearing ester with only minimal reductions in potency.<br><div><br></div>

Sign in / Sign up

Export Citation Format

Share Document